Drug major Cipla said its subsidiary InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to USD 215 million (around Rs.1,560 cr.). Avenue Therapeutics is focused on development and commercialization of intravenous (IV) Tramadol, a painkiller.
Cipla’s subsidiary to acquire US-based Avenue Therapeutics for $215 million
Date posted: Wednesday 14 November 2018